|
|
 |
|
Viewing report
|
|
 |
 |
Atherosclerosis: Strategic Audit of Marketplace Activity Issues and Implications
ADIS, Jan 2001, Pages: 322
This new study delivers:
- A review of its etiology, its relation to other cardiovascular diseases, and its consequences
- Prevalence and costs
- Principals guiding management of conditions and overview of current therapies
- Opinion leaders' evaluation of current diagnosis, therapy and health management
- Emerging models for managing care at the health plan/provider levels
- Pipeline of selected emerging technologies and their role in therapeutics in the 21st century
- Profiles of manufacturers with current portfolio and pipeline interest
- Provider and health care delivery perspectives
- Managed Care perspective-mco, PBM, carve-outs, and other organizations with notable presence in the management of the condiiton
- Recent events in the management of the condition.
Customers who bought this item also bought
Cardiovascular Therapy Worldwide Market Survey: Analysis and Forecast - Technology, Sales and Company Profiles
Cardiology Drug Licensing Opportunities, 2002
Cardiovascular Therapy US Market Survey: Analysis and Forecast - Technology, Sales and Company Profiles
Asthma: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Products, Performance and Closing the Need Gap
Drugs, Devices and Procedures of Tomorrow: Acute Stroke - Chasing the need for speed
Diabetes: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance, and Closing the Need Gap
Osteoporosis: Strategic Audit of Marketplace Activity, Issues and Implications
Pipeline Insight: Antithrombotics - Entering the Era of Exanta
Osteoarthritis and Rheumatoid Arthritis: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Market Dynamics 2001: Anti-hypertensives - Aiirbs battle for supremacy
Drugs of Tomorrow 2001: Anticoagulants - A pipeline flowing with future blockbusters
Commercial Perspectives: Anti-dyslipidemics - A tale of two launches
|
 |
|
|